David C.S. Huang
The University of Melbourne(AU)University of Melbourne(AU)Walter and Eliza Hall Institute of Medical Research(AU)Huazhong Agricultural University(CN)Lenox Hill Hospital(US)Duke-NUS Medical School(SG)National Cancer Centre Singapore(SG)Indonesia International Institute for Life Sciences(ID)BioNTech (United States)(US)Foghorn Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Cell death mechanisms and regulation, Chronic Lymphocytic Leukemia Research, RNA Interference and Gene Delivery, Ubiquitin and proteasome pathways
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function(2005)1,794 cited
- → Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity(1999)1,494 cited
- → The Bcl-2 family: roles in cell survival and oncogenesis(2003)1,448 cited
- → The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized(2006)1,217 cited
- → Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x L , but not Bcl-2, until displaced by BH3-only proteins(2005)1,207 cited